209 related articles for article (PubMed ID: 37328270)
1. The role of gut microbiota in cerebrovascular disease and related dementia.
Cuartero MI; García-Culebras A; Nieto-Vaquero C; Fraga E; Torres-López C; Pradillo J; Lizasoain I; Moro MÁ
Br J Pharmacol; 2024 Mar; 181(6):816-839. PubMed ID: 37328270
[TBL] [Abstract][Full Text] [Related]
2. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline.
Semerano A; Fernández-Ruiz J; Cortes-Canteli M; Moro MA
Br J Pharmacol; 2024 Mar; 181(6):755-759. PubMed ID: 38204183
[TBL] [Abstract][Full Text] [Related]
3. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment.
Koszewicz M; Jaroch J; Brzecka A; Ejma M; Budrewicz S; Mikhaleva LM; Muresanu C; Schield P; Somasundaram SG; Kirkland CE; Avila-Rodriguez M; Aliev G
Pharmacol Res; 2021 Feb; 164():105277. PubMed ID: 33166735
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms linking cerebrovascular dysfunction and tauopathy: Adding a layer of epiregulatory complexity.
Kim YA; Mellen M; Kizil C; Santa-Maria I
Br J Pharmacol; 2024 Mar; 181(6):879-895. PubMed ID: 37926507
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets?
García-Culebras A; Cuartero MI; Peña-Martínez C; Moraga A; Vázquez-Reyes S; de Castro-Millán FJ; Cortes-Canteli M; Lizasoain I; Moro MÁ
Br J Pharmacol; 2024 Mar; 181(6):777-798. PubMed ID: 37282844
[TBL] [Abstract][Full Text] [Related]
6. Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease.
Bettinetti-Luque M; Trujillo-Estrada L; Garcia-Fuentes E; Andreo-Lopez J; Sanchez-Varo R; Garrido-Sánchez L; Gómez-Mediavilla Á; López MG; Garcia-Caballero M; Gutierrez A; Baglietto-Vargas D
Br J Pharmacol; 2024 Mar; 181(6):840-878. PubMed ID: 37706346
[TBL] [Abstract][Full Text] [Related]
7. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?
Toribio-Fernandez R; Ceron C; Tristão-Pereira C; Fernandez-Nueda I; Perez-Castillo A; Fernandez-Ferro J; Moro MA; Ibañez B; Fuster V; Cortes-Canteli M
Br J Pharmacol; 2024 Mar; 181(6):760-776. PubMed ID: 36633908
[TBL] [Abstract][Full Text] [Related]
8. Microbiota-dependent and -independent effects of dietary fibre on human health.
Cai Y; Folkerts J; Folkerts G; Maurer M; Braber S
Br J Pharmacol; 2020 Mar; 177(6):1363-1381. PubMed ID: 31663129
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis.
Kiouptsi K; Reinhardt C
Br J Pharmacol; 2018 Dec; 175(24):4439-4449. PubMed ID: 30129122
[TBL] [Abstract][Full Text] [Related]
10. Update on the role of T cells in cognitive impairment.
Ruiz-Fernández I; Sánchez-Díaz R; Ortega-Sollero E; Martín P
Br J Pharmacol; 2024 Mar; 181(6):799-815. PubMed ID: 37559406
[TBL] [Abstract][Full Text] [Related]
11. The roles of gut microbiota and circadian rhythm in the cardiovascular protective effects of polyphenols.
Man AWC; Xia N; Daiber A; Li H
Br J Pharmacol; 2020 Mar; 177(6):1278-1293. PubMed ID: 31465555
[TBL] [Abstract][Full Text] [Related]
12. Activation of aryl hydrocarbon receptor (AhR) in Alzheimer's disease: role of tryptophan metabolites generated by gut host-microbiota.
Salminen A
J Mol Med (Berl); 2023 Mar; 101(3):201-222. PubMed ID: 36757399
[TBL] [Abstract][Full Text] [Related]
13. Drug-gut microbiota interactions: implications for neuropharmacology.
Walsh J; Griffin BT; Clarke G; Hyland NP
Br J Pharmacol; 2018 Dec; 175(24):4415-4429. PubMed ID: 29782640
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota and Alzheimer's Disease: Pathophysiology and Therapeutic Perspectives.
Li Y; Wang R; Li Q; Wang YJ; Guo J
J Alzheimers Dis; 2021; 83(3):963-976. PubMed ID: 34366348
[TBL] [Abstract][Full Text] [Related]
15. Implications of gut and oral microbiota in neuroinflammatory responses in Alzheimer's disease.
Bello-Corral L; Alves-Gomes L; Fernández-Fernández JA; Fernández-García D; Casado-Verdejo I; Sánchez-Valdeón L
Life Sci; 2023 Nov; 333():122132. PubMed ID: 37793482
[TBL] [Abstract][Full Text] [Related]
16. Nutraceuticals as modulators of gut microbiota: Role in therapy.
Quigley EMM
Br J Pharmacol; 2020 Mar; 177(6):1351-1362. PubMed ID: 31659751
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer's disease.
Goyal D; Ali SA; Singh RK
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110112. PubMed ID: 32949638
[TBL] [Abstract][Full Text] [Related]
18. Direct Modulation of the Gut Microbiota as a Therapeutic Approach for Alzheimer's Disease.
Wang Y; Dykes GA
CNS Neurol Disord Drug Targets; 2022; 21(1):14-25. PubMed ID: 34365962
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine.
Duce JA; Zhu X; Jacobson LH; Beart PM
Br J Pharmacol; 2019 Sep; 176(18):3409-3412. PubMed ID: 31468515
[TBL] [Abstract][Full Text] [Related]
20. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease.
Kesika P; Suganthy N; Sivamaruthi BS; Chaiyasut C
Life Sci; 2021 Jan; 264():118627. PubMed ID: 33169684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
